RecruitingPhase 1NCT07456878

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

Sponsor

Mayo Clinic

Enrollment

5 participants

Start Date

Jan 8, 2026

Study Type

INTERVENTIONAL

Conditions

Pituitary Adenoma

Summary

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.
Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.
Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.
Able to provide informed consent and be capable of completing the imaging protocols.
Female subjects of childbearing potential (women of childbearing potential \[WOCBP\]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection.

Exclusion Criteria4

Patients with contraindications to MRI or PET scans.
Patients with known allergies to contrast agents or other imaging-related materials.
Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).
Patients with successful MRI localization of the adenoma.